Latest Pharmacy News

Comvita Limited has swung back to profitability in FY26, reporting $7.7 million net profit after a $40.5 million capital raise that brought Southeast Asian consumer giant F&N Ventures on board with a near 20% stake.

Nuchev Limited grew revenue by 12% in FY26, driven by domestic expansion, yet saw margins contract and adjusted EBITDA losses deepen to A$4.6 million. The company’s FY27 focus shifts to margin improvement, operating leverage, and cash conversion.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

Biome Australia has delivered a standout FY26 with sales up 30% to $23.9 million and net profit after tax soaring to $3.6 million, bolstered by a non-cash deferred tax asset. The company strengthened its balance sheet while expanding manufacturing and international distribution.

NAOS Emerging Opportunities Company Limited (ASX: NCC) delivered a robust FY26 with a 2416% surge in after-tax profit and an 18.7% portfolio return, outperforming the benchmark by over 10%. The company raised its fully franked dividend by 5%, signaling confidence amid a challenging market.

EBOS Group posted a solid FY26, growing revenue nearly 10% to $13.5 billion and underlying EBITDA 5% to $614 million, while completing a major distribution centre renewal program. The company maintains its final dividend and sets a confident growth outlook for FY27.

Xenitra’s Hong Kong subsidiary Fukang has inked a three-year A$5 million procurement framework for specialised medical nutrition products, broadening its foothold beyond OTC medicines in China’s booming healthcare market.

Vita Life Sciences delivered a robust first half in 2026 with revenue up 6.1% to A$48.3 million and net profit after tax rising 14.9% to A$5.54 million. The company declared a higher interim dividend, reflecting improved margins and regional market momentum.

Green Cross Health CEO Rachael Newfield will step down in January 2027 following the sale of the Medical division, paving the way for a new pharmacy-centric leadership role.

LTR Pharma reports a 93% response rate in men seeking convenience and spontaneity with SPONTAN, alongside a 64% response in post-prostatectomy patients, highlighting potential for its rapid-onset intranasal ED treatment in challenging populations.

Elixinol Wellness (ASX: EXL) has posted a record quarterly revenue of A$4.3 million alongside a 45% gross margin, marking a clear shift from its US CBD origins to a diversified Australian wellness platform. Cost reductions and disciplined cash flow management underpin the company’s readiness to scale.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.